Genoptix, Clinical Data: Small-Cap Winners

NEW YORK ( TheStreet) -- Clinical Data ( CLDA) was the biggest gainer among small-caps Monday afternoon, its shares soaring 55% to $23.30, after U.S. regulators approved its major depressive disorder treatment Viibryd. The biotech company said the drug would be available in U.S. pharmacies by the second quarter. Over 9 million shares changed hands.

Shares of Genoptix ( GXDX) jumped 26% to $24.83 on heavy volumes after Swiss pharma giant Novartis ( NVS) said it was acquiring the diagnostics laboratory for $470 million or $25 per share in an all cash deal.

Rexahn Pharmaceuticals ( RNN) shot up 20% to $1.57 after Israel-based Teva Pharmaceuticals ( TEVA) said it had acquired a 6% stake in the company at $1.69 per share.

Several solar stocks were shining on the bourses after Goldman Sachs added First Solar ( FSLR) to its conviction list. Shares of LDK Solar ( LDK) were surging 10.5% to $14.53. Solarfun Power ( SOLF), Trina Solar ( TSL) and ReneSola ( SOL) were also up sharply.

Shares of Depomed ( DEPO) were recovering Monday after plunging last week, rising 7.2% to $6.23. The stock took a hit last week after it said that Abbot Laboratories ( ABT) was reluctant to market its pain reliever drug.

Level 3 Communications ( LVLT), Dot Hill Systems ( HILL), Pluristem Therapeutics ( PSTI) and ATP Oil and Gas ( ATPG) were among the other major gainers on Monday.

-- Written by Shanthi Bharatwaj in New York

>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to http://twitter.com/shavenk.

>To submit a news tip, send an email to: tips@thestreet.com.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Investing

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

McDonald's Criticized for Not Doing More in Wake of Sexual Harassment Claims

McDonald's Criticized for Not Doing More in Wake of Sexual Harassment Claims

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%